The aim of this study is to evaluate the significance of the concentrations of selected biomarkers—an inflammatory marker (osteopontin), a marker of blood–brain barrier damage (occludin), and a marker of neurodegeneration (NFL)—in the serum of patients with the relapsing-remitting form of MS, to predict disease activity and disability progression. Here, SPP1 is linked to myeloid sarcoma.